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ACCOMMODATION TO DIAGNOSIS 
OF TRIGEMINAL NEURALGIA
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SUMMARY – Trigeminal neuralgia is one of the most common causes of facial pain. It implies 
short lasting episodes of unilateral electric shock-like pain with abrupt onset and termination, in the 
distribution of one or more divisions of the trigeminal nerve that are triggered by innocuous stimuli. 
Most cases of trigeminal neuralgia are caused by compression of the trigeminal nerve root. Depending 
on the etiology, trigeminal neuralgia can be classifi ed as classic trigeminal neuralgia or painful tri-
geminal neuropathy. It may be precipitated by some actions at trigger zones. Th e diagnosis of tri-
geminal neuralgia is based on diagnostic criteria for classic trigeminal neuralgia, neuroimaging and 
electrophysiologic trigeminal refl ex testing. Treatment of classic trigeminal neuralgia for most patients 
is pharmacological therapy, while surgical approach is reserved for patients that are refractory to med-
ical therapy and in cases of painful trigeminal neuropathy.
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Introduction
Trigeminal neuralgia (TN) is one of the most com-
mon causes of facial pain, with the annual incidence of 
4 to 13 per 100 000 people and increasing gradually 
with age1,2. It is one of the most frequent neuralgias in 
the elderly population, with the male to female ratio 
1:1.73. Trigeminal nerve starts at the midlateral surface 
of the pons, and its sensory ganglion (gasserian gangli-
on) resides in Meckel’s cave in the fl oor of the middle 
cranial fossa. It brings sensory supply to the face and the 
sensory and motor supply to the muscles of mastication. 
It divides into three main branches, ophthalmic, maxil-
lary and mandibular. TN is characterized by recurrent 
short lasting episodes of unilateral electric shock-like 
pain with abrupt onset and termination, in the distribu-
tion of one or more divisions of the trigeminal nerve 
that are triggered by innocuous stimuli4.
Etiology and Pathogenesis
Most TN cases are caused by compression of the 
trigeminal nerve root, usually within a few millimeters 
of entry into the pons5. Compression can be caused by 
an aberrant loop of an artery or vein (80 to 90 percent 
of cases)5-7, or vestibular schwannoma (acoustic neu-
roma), meningeoma, epidermoid or other cyst, or rare-
ly a saccular aneurysm or arteriovenous malforma-
tion8-14. Idiopathic TN or TN caused by vascular com-
pression is considered classic TN, and other causes of 
TN via compression are classifi ed as painful trigemi-
nal neuropathy. Th e mechanism by which compression 
of the nerve leads to symptoms appears to be related to 
demyelination in a circumscribed area around the 
compression15,16. Th e mechanism by which demyelin-
ation results in the symptoms of TN is not entirely 
clear. It is also possible that there is a role of the central 
pain mechanisms. Demyelination of one or more of 
the trigeminal nerve nuclei may also be caused by mul-
tiple sclerosis or other structural lesions of the brain-
stem, although vascular compression has also been 
noted in these patients17.
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Classifi cation of Trigeminal Neuralgia
Th e International Classifi cation of Headache Dis-
orders, 3rd edition (ICHD-3) classifi es TN into two 
categories: classic TN that encompasses idiopathic TN 
and TN caused by neurovascular compression, and 
painful trigeminal neuropathy caused by many other 
conditions mentioned before4. Painful trigeminal neu-
ropathy encompasses painful trigeminal neuropathy 
attributed to acute herpes zoster, postherpetic trigemi-
nal neuropathy, painful posttraumatic trigeminal neu-
ropathy, painful trigeminal neuropathy attributed to 
multiple sclerosis plaque, painful trigeminal neuropa-
thy attributed to space-occupying lesion and painful 
trigeminal neuropathy attributed to other disorder4.
Clinical Presentation 
of Trigeminal Neuralgia
Trigeminal neuralgia is clinically defi ned by parox-
ysmal, stereotyped attacks of usually intense, sharp, 
superfi cial or stabbing pain in the distribution of one 
or more branches of the trigeminal nerve4. Th e pain of 
TN tends to occur in paroxysms and is immediately 
maximal in intensity. Th e pain is often described as 
unilateral repetitive electric, shock-like or stabbing, 
lasting from one to several seconds. A refractory peri-
od of several minutes during which a paroxysm cannot 
be provoked is common. Some patients with long-
lasting TN may have continuous dull pain that is pres-
ent between paroxysms of pain. TN does not awake 
patients. Facial muscle spasms can sometimes accom-
pany the pain. Trigger zones in the distribution of the 
aff ected nerve may be present and are often located 
near the midline. Triggers include lightly touching 
these zones, chewing, talking, brushing teeth, cold air, 
smiling, and/or grimacing. TN can also be precipitated 
by dental procedures and ‘pretrigeminal neuralgia’, 
which is dull, continuous, aching pain in the jaw evolv-
ing eventually into TN. It is suspected to have a dental 
origin and unnecessary dental procedures have been 
performed in many cases18. Episodes of TN may last 
for weeks or months, followed by pain-free intervals. 
Recurrence is common, and some patients may have 
concomitant persistent background facial pain. Gener-
ally, the condition tends to decrease in severity and 
frequency of pain exacerbations.
Trigeminal Neuralgia Diagnosis 
and Diff erential Diagnosis
Th e initial diagnosis of TN is based on the charac-
teristic clinical features. Th en, search for secondary 
causes usually takes place. Younger patients and pa-
tients with trigeminal sensory loss or bilateral involve-
ment are probably at a higher risk of painful trigeminal 
neuropathy, but the absence of any of these clinical 
features does not rule it out. Hypoesthesia or hypoal-
gesia in the aff ected trigeminal region always indicates 
axonal damage and therefore trigeminal neuropathy, 
while hyperalgesia in the painful region should not 
immediately lead to the diagnosis of trigeminal neu-
ropathy because it may refl ect increased attention to 
the painful side4.
Th e ICHD-3 diagnostic criteria for classic TN 
from Th e International Classifi cation of Headache 
Disorders comprise the following4:
A) At least three attacks of unilateral facial pain 
fulfi lling criteria B and C
B) Occurring in one or more divisions of the tri-
geminal nerve, with no radiation beyond the 
trigeminal distribution
C) Pain has at least three of the following four 
characteristics:
• recurring in paroxysmal attacks lasting from 
a fraction of a second to two minutes
• severe intensity
• electric shock-like, shooting, stabbing or 
sharp in quality
• at least three attacks precipitated by innocu-
ous stimuli to the aff ected side of the face 
(some attacks may be, or appear to be, spon-
taneous)
D) No clinically evident neurologic defi cit
E) Not better accounted for by another ICHD-3 
diagnosis
Neuroimaging and trigeminal refl ex testing are 
considered useful for distinguishing patients with clas-
sic TN from those with painful trigeminal neuropa-
thy19. Neuroimaging with head computed tomography 
(CT) or magnetic resonance imaging (MRI) may be 
useful for identifying patients that have a structural le-
sion as the cause of painful trigeminal neuropathy19,20. 
High-resolution brain MRI and magnetic resonance 
angiography (MRA) may be useful to identify vascular 
compression as the etiology of classic TN. Brain MRI 
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is recommended to rule out causative structural brain 
lesions in patients with trigeminal sensory loss, pa-
tients with bilateral symptoms and patients under the 
age of 40.
Electrophysiologic trigeminal refl ex testing (blink 
refl ex and the masseter inhibitory refl ex) is probably 
useful for distinguishing classic TN from painful tri-
geminal neuropathy. Th ese tests are usually normal in 
patients with classic TN. Five studies underline the ac-
curacy of trigeminal refl ex testing in the evaluation of 
TN19. One of them was a prospective report21, whereas 
the other four studies were retrospective22-25. Based on 
high sensitivity and specifi city from these studies, the 
AAN/EFNS have concluded that abnormal trigemi-
nal refl exes are associated with an increased risk of 
painful trigeminal neuropathy. In contrast, testing with 
trigeminal evoked potentials is not useful for making 
this distinction, as it has been underlined in four stud-
ies19.
Th e diff erential diagnosis of classic TN includes 
short-lasting unilateral neuralgiform headache with 
conjunctival injection and tearing (SUNCT), cluster-
tic syndrome, jabs and jolts syndrome, and other pain-
ful facial neuralgias.
Th erapy of Trigeminal Neuralgia
In most patients, the initial treatment of classic TN 
is pharmacological therapy. Surgical approach is re-
served for patients that are refractory to medical ther-
apy. In cases of painful trigeminal neuropathy, no med-
ications have been established as eff ective but treat-
ment of the underlying condition is recommended. In 
addition, it is reasonable to treat the pain associated 
with painful trigeminal neuropathy using the same 
medications that are employed for classic TN.
In patients with classic TN, carbamazepine is rec-
ommended as the initial, fi rst-line therapy (grade 1A). 
Side eff ects (drowsiness, dizziness, nausea and vomit-
ing) can appear but are generally manageable, particu-
larly if low doses are prescribed initially with gradual 
titration. Carbamazepine-induced leukopenia is not 
uncommon, but it is usually benign. Aplastic anemia is 
a rare adverse eff ect, as well as Stevens-Johnson syn-
drome and/or toxic epidermal necrolysis, especially in 
Asian patients. Th e usual carbamazepine starting dose 
is 100 to 200 mg twice daily. Th e dose can be increased 
gradually in increments of 200 mg daily. Th e typical 
total maintenance dose is 600 to 800 mg daily, given in 
two divided doses in the form of tablets and extended 
release capsules, or four divided doses in the form of 
oral suspension. Th e maximum suggested total dose is 
1200 mg daily. For patients who do not respond to or 
tolerate carbamazepine, oxcarbazepine is recommend-
ed (grade 1B). It can be started at a total dose of 600 
mg daily, given in two divided doses. Th e dose can be 
increased in 300-mg increments every third day to a 
total dose of 1200 to 1800 mg daily. For patients who 
are refractory to or intolerant of carbamazepine and 
oxcarbazepine, switching to treatment with baclofen 
(grade 2C) or lamotrigine as add-on therapy is recom-
mended. In patients who are not taking other anticon-
vulsants, lamotrigine is typically started at 25 mg daily 
for the fi rst two weeks, and then increased to 50 mg 
daily for the next two weeks. Th e dose is then titrated, 
increasing by 50 mg daily every one to two weeks. Th e 
suggested total dose of 400 mg daily is given in two 
divided doses. For patients taking an anticonvulsant 
drug that induces hepatic enzymes (carbamazepine, 
phenytoin or primidone), the initial dose of lamotrigi-
ne is 50 mg once daily, titrating upward to 100 mg 
once daily at the third week, 200 mg once daily at the 
fi fth week, 300 mg once daily at the sixth week, and 
400 mg once daily at the seventh week. For patients 
taking valproate, the initial dose of lamotrigine is 12.5 
to 25 mg every other day, with increases of 25 mg every 
two weeks to a maximum of 400 mg per day. For pa-
tients with TN that are refractory to the fi rst- and 
second-line therapy, an ample of other medications 
with limited evidence of benefi t may be considered. 
Botulinum toxin injections may be benefi cial for pa-
tients with medically refractory TN, although data are 
limited26. A systematic review and practice parameter 
published in 2008 by the American Academy of Neu-
rology (AAN) and the European Federation of Neu-
rological Societies (EFNS) has concluded that carba-
mazepine is eff ective for controlling pain in patients 
with classic TN, oxcarbazepine is probably eff ective, 
and baclofen, lamotrigine and pimozide are possibly 
eff ective19. Th ere are limited data and uncertain eff ec-
tiveness regarding other drugs that have been used for 
TN, including clonazepam, gabapentin, phenytoin, to-
cainide, tizanidine and valproate. Th ey have shown 
some evidence of effi  cacy for TN in small, generally 
lower-quality controlled trials. Th e choice among these 
agents is driven by patient preference, side eff ect pro-
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fi le, cost, and physician familiarity. Although there are 
no controlled data regarding the effi  cacy of opioids in 
TN specifi cally, some specialists use opiates in patients 
with acute exacerbations of pain lasting for days to 
weeks. Opiates may help make the pain endurable 
while more eff ective long-term treatments work out. 
Th eir experience suggests partial analgesia with central 
side eff ects when these drugs are used alone, as high 
doses are usually required. Opiates seem to be more 
eff ective at lower doses in combination with other 
neuropathic analgesics.
In patients with TN refractory to medical therapy, 
it is reasonable to discuss options for surgical therapy 
using microvascular decompression or ablative proce-
dures (rhizotomy with radiofrequency thermocoagula-
tion, mechanical balloon compression, or chemical 
(glycerol) injection, radiosurgery, peripheral neurecto-
my and nerve block). Microvascular decompression is 
invasive, although the overall mortality and complica-
tion rates are low. Ablative procedures are less invasive, 
but recurrence may be more common. Although surgi-
cal therapy for TN is generally well-tolerated, one of 
the worse complications is painful posttraumatic tri-
geminal neuropathy (anesthesia dolorosa), a condition 
characterized by persistent, painful anesthesia or hyp-
esthesia in the denervated region4. Few surgical treat-
ments for TN have been studied in controlled trials, 
and most evidence comes from observational studies27. 
It is considered that microvascular decompression, rhi-
zotomy, and gamma knife radiosurgery are possibly ef-
fective in the treatment of TN19. Evidence for periph-
eral neurectomy was considered negative or inconclu-
sive. Indirect comparisons of the fi ndings from diff er-
ent surgical studies suggest that microvascular 
decompression has a longer duration of pain control 
than other surgical interventions for TN. Th e decision 
to have surgery and the choice among surgical options 
will be infl uenced by individual circumstances includ-
ing patient preference, side eff ect profi le of the tech-
niques available, and expertise of the local center.
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Trigeminalna neuralgija jedan je od najčešćih uzroka boli u području lica. Defi nicija trigeminalne neuralgije podrazumi-
jeva kratkotrajne epizode jednostrane boli nalik elektroškovima s iznenadnim početkom i završetkom u distribuciji jedne ili 
više grana trigeminalnog živca, a potaknute bezopasnim poticajem. U većini slučajeva trigeminalna neuralgija uzrokovana je 
pritiskom na korijen trigeminalnog živca. Ovisno o etiologiji, trigeminalna se neuralgija klasifi cira kao klasična trigeminalna 
neuralgija odnosno kao bolna trigeminalna neuropatija. Moguće ju je izazvati određenim aktivnostima u području zona 
okidanja. Dijagnoza trigeminalne neuralgije postavlja se na osnovi dijagnostičkih kriterija, slikovnih prikaza struktura središ-
njega živčanog sustava te elektrofi zioloških testiranja trigeminalnih refl eksa. Liječenje klasične trigeminalne neuralgije za 
većinu bolesnika je farmakološke naravi, dok je operativni pristup rezerviran za bolesnike refraktorne na medikamentnu 
 terapiju te bolesnike s bolnom trigeminalnom neuropatijom.
Ključne riječi: Trigeminalna neuralgija – terapija; Trigeminalna neuralgija – kirurgija; Središnji živčani sustav – vaskularne 
anomalije; Refl eks treptanja; Karbamazepin
